Get the Stockscreener App
108.03
0.10%
-0.11
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $108.03, with a volume of 8.83M.
It is down -0.10% in the last 24 hours and down -4.13% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$108.14
Open:
$109.39
24h Volume:
8.83M
Relative Volume:
0.96
Market Cap:
$187.72B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
29.06
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-1.40%
1M Performance:
-4.13%
6M Performance:
-19.22%
1Y Performance:
-16.83%
1-Day Range:
$107.70
$110.31
1-Week Range:
$107.70
$112.74
52-Week Range:
$105.27
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.03 | 187.72B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
336.77 | 128.88B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.14 | 111.88B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.13 | 102.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
81.81 | 47.52B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories: A Tale of Clinical Success and Market Hesitation - AD HOC NEWS
Abbott Laboratories Stock (ISIN: US0028241000) Nears 52-Week Low Amid Guidance Concerns, But Analyst - AD HOC NEWS
UBS Maintains Buy on Abbott Laboratories (ABT) March 13, 2026 - Meyka
Abbott (NYSE: ABT) outlines 2026 votes, board pay and long-term sustainability goals - Stock Titan
Abbott Launches ICRAS Tool to Assess Heart and Kidney Risks in Diabetes Patients - The Indian Practitioner
Abbott Could Get An Unexpected Lift From A Rival’s Trial - Finimize
UBS reiterates Abbott Labs stock rating on structural heart upside - Investing.com
Abbott Laboratories stock consolidates as bearish momentum continues after weak technical signals - Traders Union
Abbott Laboratories Stock (ISIN: US0028241000) Faces Pressure Amid Diagnostics Slowdown and Obesity - AD HOC NEWS
Benchmark reiterates Abbott stock rating on diabetes trial results - Investing.com
Intravenous (IV) Solutions Market Size to Reach USD 29.47 Billion by 2035 Due to the Increasing Prevalence of Chronic Diseases Globally | SNS Insider - GlobeNewswire Inc.
How The Story On Abbott Laboratories (ABT) Is Shifting As Analysts Rework Targets And Risks - Yahoo Finance
Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin - MassDevice
Abbott (ABT) Showcases Positive Outcomes with FreeStyle Libre in Diabetes Management - GuruFocus
Abbott Laboratories $ABT Holdings Trimmed by Elevatus Welath Management - MarketBeat
Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & SuppliesDiversified Stocks - Yahoo Finance UK
Abbott’s Freedom To Work Plan And What It May Mean For NYSE ABT - simplywall.st
Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management - Bolsamania
Diverging Views Emerge on Abbott Laboratories' Stock Outlook - AD HOC NEWS
Q4 Financial Results: Comparing Abbott Laboratories (NYSE:ABT) With Other Diversified Medical Devices & Supplies Stocks - Bitget
Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' - Investing News Network
Citigroup Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Abbott and Real Madrid launch nationwide effort to build the next 'Abbott Dream Team' – Company Announcement - Financial Times
Intuitive Surgical Upgraded to Buy by Citi — Plus Key Moves on Stryker and Abbott - 24/7 Wall St.
Van ECK Associates Corp Has $50.42 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Mackenzie Financial Corp Buys 29,440 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Franklin Resources Inc. - MarketBeat
Vitamin D Testing Market Is Going to Boom |• Abbott • Roche Diagnostics • Siemens Healthineers - openPR.com
Capital World Investors Grows Holdings in Abbott Laboratories $ABT - MarketBeat
Opening arguments begin in first Illinois trial against Abbott over its formula for premature babies - The Daily Gazette
Is Abbott Laboratories (ABT) Pricing Reflect Its Mixed Share Performance And Growth Prospects? - Yahoo Finance
MiniMed expands sensor portfolio in Europe with CE Mark for MiniMed™ 780G system with the Instinct sensor, made by Abbott - BioSpace
Capital International Sarl Buys 12,412 Shares of Abbott Laboratories $ABT - MarketBeat
Is It Time To Revisit Abbott Laboratories (ABT) After Recent Share Price Weakness? - simplywall.st
Abbott Laboratories (ABT) Announces $20 Billion Senior Notes Off - GuruFocus
Abbott Formula Linked To 'Horrible' Gut Disease, Ill. Jury Told - Law360
Abbott Laboratories Completes Major Senior Notes Offering - TipRanks
Four-Plaintiff Chicago Trial Opens Against Abbott Over Preterm Infant Formula - Law.com
Abbott Laboratories Offers Long-Term Upside Despite Recent Stumbles (NYSE:ABT) - Seeking Alpha
Vinva Investment Management Ltd Has $10.21 Million Stake in Abbott Laboratories $ABT - MarketBeat
Russell Investments Group Ltd. Purchases 92,788 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Dundas Partners LLP - MarketBeat
Abbott Laboratories Pakistan : Board Meeting - marketscreener.com
B. Metzler seel. Sohn & Co. AG Raises Stock Position in Abbott Laboratories $ABT - MarketBeat
First Trust Advisors LP Buys 810,684 Shares of Abbott Laboratories $ABT - MarketBeat
NEC Baby Formula Lawsuit & Settlement | March 2026 Update - Lawsuit Information Center
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Volatility - simplywall.st
Abbott IP chief: ‘Firms without AI policies scare me’ - Life Sciences Intellectual Property Review
Abbott Laboratories $ABT Shares Sold by Victory Capital Management Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Orion Porfolio Solutions LLC - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):